Arthneeti
All Q4 FY26 results →
L

Lupin

Q4 FY26Pharmaceuticals & Biotechnology

Lupin Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,103
Market cap₹95.2K Cr
P/E16.0
Updated23 Sept 2026
Read4 min read

The short version

Lupin expects high single-digit revenue growth in FY27 with around 25% EBITDA margin. - The U.S. Lupin expects high single-digit revenue growth in FY27 despite competitive pressures and geopolitical uncertainties. - EBITDA margins are guided around 25% for FY27, slightly lower than FY26 due to competition in key products like Tolvaptan and Mirabegron. - Biosimilars and complex products, including respiratory and injectables, are expected to drive growth in the U.S.

From Lupin's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

  • Lupin expects high single-digit revenue growth in FY27 with around 25% EBITDA margin.
  • The U.S. business aims to sustain over USD 1 billion revenues in FY27 despite competition and erosion, supported by new product launches including biosimilars and complex injectables.
  • Biosimilars are viewed as a major future growth driver, with multiple products like Pegfilgrastim, Ranibizumab, Aflibercept, and Etanercept expected to contribute meaningfully.
  • India business growth is expected to continue outperforming the Indian Pharmaceutical Market (IPM) by 1.2x to 1.3x, supported by ~20 planned product launches in FY27 and a strong pipeline.
  • VISUfarma acquisition is forecasted to grow to over USD 100 million sales in 2-3 years, expanding Lupin's European presence.

2 more points from Lupin's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Lupin said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company is focused on strategic capital allocation to support long-term goals, particularly in specialty segments and developed markets.
  • Recent acquisition of VISUfarma expands geographic presence and specialty portfolio, with plans to leverage this in Europe and emerging markets.
  • There is active exploration of specialty assets in ophthalmology, pulmonology, and rare neuro segments.
  • Pipeline investments include complex injectables, biosimilars, and 505(b)(2) products, indicating ongoing R&D and product development investments.

2 more points from Lupin's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Lupin said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention details regarding the current or expected order book or pending orders for Lupin Limited. However, relevant points referring to business outlook and product pipeline include: - Lupin filed 11 products and launched 15 products during FY26 in the US market. - Expectation to launch 50+ products in the US over the next three years, including 10 exclusive first-to-files, 4 biosimilars, and 2-3 505(b)(2) products. - Biosimilars and complex injectables expected to be key contributors going forward. - Pegfilgrastim partnership with Valorum expected to ramp up from Q2-Q3 FY27. - VISUfarma acquisition expected to add significant sales growth in ophthalmology and specialty segments.

2 more points from Lupin's call on order book

Pro opens every point from 15K+ earnings calls

Lupin — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹1.5K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Lupin Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pha. (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn Ltd (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Lupin and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Lupin Q4 FY26 results?

Lupin expects high single-digit revenue growth in FY27 with around 25% EBITDA margin. - The U.S. Lupin expects high single-digit revenue growth in FY27 despite competitive pressures and geopolitical uncertainties. - EBITDA margins are guided around 25% for FY27, slightly lower than FY26 due to competition in key products like Tolvaptan and Mirabegron. - Biosimilars and complex products, including respiratory and injectables, are expected to drive growth in the U.S.

What is Lupin share price analysis?

Lupin currently shows a neutral. The stock trades at a P/E of 16.0 with a market cap of ₹95,248 Cr. Investors should review the full earnings analysis for detailed insights.

Is Lupin planning capital expenditure?

The company is focused on strategic capital allocation to support long-term goals, particularly in specialty segments and developed markets.

Keep Lupin on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.